Compare OneSpan Inc (OSPN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Regeneron Pharmaceuticals Inc — how do they compare? OneSpan Inc trades at $16.12 (market cap $593.32M), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 140.6× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.23%). Which is the better fit depends on your goals.
| OSPN | REGN | |
|---|---|---|
Market Cap | $593.32M | $83.43B |
Sector | Technology | Health |
52-Week High | $16.92 | $852.03 |
52-Week Low | $10.15 | $555.51 |
Enterprise Value | $562.40M | $78.14B |
Dividend Yield | 3.23% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $16.1, down 3.59% on the day, with technical indicators showing a neutral trend and key support at $16. The stock exhibits strong fundamentals, including a P/E of 9.1, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights institutional interest, such as Deutsche Bank's new position, and the company's introduction of DigipassONE for authentication modernization.
The outlook for OSPN is positive, supported by solid financials and analyst consensus, but risks include competitive pressures and cash flow volatility. With a consensus price target of $17.00 and 66.67% buy ratings, the stock offers potential upside, though investors should monitor execution risks and market sentiment shifts.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
